CTNNB1 and metastatic neoplasm: CTNNB1, a key component of the Wnt signaling pathway, is characterized above (Figure 2).[15] CTNNB1 exon 3 mutations, such as T41A, are considered to be activating the Wnt pathway.[22] At the time of referral to the CCTT the patient had metastatic disease to his liver, adrenal glands and bones and subsequently received experimental therapy with hepatic arterial infusion oxaliplatin (140 mg/m2 every 3 weeks), intravenous bevacizumab (10 mg/kg every 3 weeks) and oral; capecitabine (1500 mg/m2 on days 1-4 every 3 weeks) and progressed after 2.2 months.